Senior-Level Neuromodulation Executive Joins AdvaStim

AdvaStim Inc., a developer of ASIC-based technology platforms for neuromodulation therapies, announced that George Cintra has joined the company as strategic advisor for technology and business development. Cintra has more than 25 years of experience leading product development, engineering and business development functions in the medical device and consumer products industries.
 
“Having someone of George’s industry background join our team demonstrates the commercial potential that our technology promises to the neuromodulation device field,” said Laurence Derose, CEO and Co-founder of AdvaStim. “Our ASIC-based platform can potentially open new avenues and approaches for targeted neurostimulation therapies, and George’s industry contacts and long experience in the field can help us best leverage these opportunities.”
 
Cintra was executive vice president and chief technology officer at Integer Holdings Inc. (formerly Greatbatch Medical), a designer and developer of implantable medical devices, from 2013 through January 2016, and served in an advisory capacity through January 2017. In addition to leading research, development, engineering, and regulatory & clinical affairs, he also led the QiG Group and CCC Medical Devices subsidiaries for the company. Prior to Integer, he had a 16-year career holding technology and product development positions at P&G, Gillette, and Duracell. He has been awarded 39 U.S. and foreign patents across a broad range of power systems and electromechanical products. Cintra earned his bachelor of science degree in chemical engineering and completed graduate studies at Carnegie Mellon and the University of Virginia.

“AdvaStim’s ASIC-based technology represents a breakthrough for neuromodulation therapeutic systems to expand into a variety of clinical indications,” said Cintra. “I’m excited to join AdvaStim and help further this technology for the next generation of neuromodulation therapy options.”
 
AdvaStim is a technology developer addressing the multi-billion dollar neurostimulation market with a hardware/software technology platform to help emerging device companies effectively implement the next generation of implantable device therapeutics. The company is based in Beverly, Mass.